FDA July 2026 Peptide Advisory Meeting: All 7 Peptides Under Review
Shop Our Top Compounds
FDA July 2026 Peptide Advisory Meeting: All 7 Peptides Under Review — Research Guide
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to convene on July 23–24, 2026 to review seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List. This marks one of the most significant regulatory developments in the peptide research field since the Biden administration’s 2023 removal of 19 peptides from the compounding allowed list. For researchers sourcing these peptides for preclinical studies, here is a detailed breakdown of every peptide on the July 2026 agenda, the specific uses the FDA is evaluating, and what this means for the research landscape.
Background: Why the FDA Is Reviewing These Peptides
In 2023, the FDA removed 19 peptides from the 503A Bulk Drug Substances List — the list of substances that licensed compounding pharmacies can use without an approved drug application. The FDA cited concerns about immunogenicity, toxicity, and impurity profiles for the removed compounds, noting that most lacked adequate human clinical data.
In early 2026, amid growing interest from the research community and statements by Health Secretary Robert F. Kennedy Jr. (who described himself as a “big fan of peptides”), the FDA announced it would convene the PCAC to reconsider several of the removed peptides. The July 23–24, 2026 meeting will examine seven of those peptides. A subsequent meeting (scheduled before February 2027) will consider five additional peptides.
The PCAC makes non-binding recommendations. The FDA is not legally required to follow them but generally does. Public comment is open through July 22, 2026 via docket FDA-2026-N-2979.
Important note for researchers: This regulatory review concerns compounding pharmacy availability. It does not affect the availability of these compounds from research peptide suppliers like Iron Peak Peptides, which supplies all peptides strictly for laboratory and preclinical research purposes — not for human consumption, clinical application, or compounding.
July 23, 2026: Day One — Four Peptides Under Review
1. BPC-157 (Body Protection Compound-157)
FDA evaluation use: Ulcerative colitis (UC)
BPC-157 is a 15-amino acid pentadecapeptide derived from human gastric juice that has generated the largest body of preclinical research of any peptide on the July 2026 agenda. Researchers have published numerous in vivo studies examining BPC-157 in gastrointestinal, musculoskeletal, and neurological models.
For the July 2026 PCAC review, the FDA is specifically evaluating BPC-157 for ulcerative colitis — a chronic inflammatory bowel disease characterized by mucosal inflammation of the colon. Published preclinical research has examined BPC-157’s effects on intestinal permeability, mucosal healing, and inflammatory cytokine profiles in colitis models.
BPC-157 is available from Iron Peak Peptides in both free base and acetate forms (≥98% HPLC purity) for laboratory and preclinical research use.
2. KPV (Lys-Pro-Val)
FDA evaluation uses: Wound healing; inflammatory conditions
KPV is a tripeptide fragment derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). As the smallest peptide on the July 23 agenda, KPV’s structural simplicity is deceptive — preclinical research has examined its anti-inflammatory signaling through MC1R receptor interactions and NF-κB pathway modulation.
The FDA is evaluating KPV for two research areas: wound healing and inflammatory conditions. Published in vitro and in vivo studies have examined KPV in murine colitis models, skin wound healing assays, and intestinal epithelial cell culture systems studying cytokine modulation (TNF-α, IL-6, IL-1β).
KPV is available from Iron Peak Peptides in lyophilized form (≥98% HPLC purity) for laboratory research purposes.
3. TB-500 (Thymosin Beta-4)
FDA evaluation use: Wound healing
TB-500 — a 43-amino acid synthetic analog of Thymosin Beta-4 — has one of the most extensive published preclinical research profiles of the July 2026 peptides. Studies have investigated its roles in actin cytoskeletal dynamics, angiogenesis, cell migration, and tissue repair across multiple organ systems.
The FDA is evaluating TB-500 specifically for wound healing applications. Research in this area has examined TB-500’s effects on keratinocyte migration, fibroblast proliferation, angiogenic signaling (including VEGF upregulation), and dermal wound closure kinetics in animal models.
TB-500 is a flagship Iron Peak Peptides product, available in lyophilized powder (≥98% HPLC purity) with full mass spectrometry verification for research use only.
4. MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c)
FDA evaluation uses: Obesity; osteoporosis
MOTS-C is a 16-amino acid mitochondrial-derived peptide (MDP) encoded by the 12S rRNA gene of mitochondrial DNA. Unlike the other peptides on the July 23 agenda, MOTS-C is endogenously produced and acts as a signaling molecule involved in energy metabolism regulation and AMPK pathway activation.
The FDA is examining MOTS-C for obesity and osteoporosis research applications. Published preclinical studies have investigated MOTS-C’s effects on insulin sensitivity, glucose homeostasis, adipose tissue metabolism, and bone mineral density in mouse models. Of particular research interest is MOTS-C’s potential as a “mitokine” — a circulating mitochondrial signal that coordinates systemic metabolic responses.
MOTS-C is available from Iron Peak Peptides for laboratory and preclinical research use.
July 24, 2026: Day Two — Three More Peptides Under Review
5. Emideltide (Delta Sleep-Inducing Peptide / DSIP)
FDA evaluation uses: Opioid withdrawal; chronic insomnia; narcolepsy
Emideltide — also known as delta sleep-inducing peptide (DSIP) — is a nonapeptide (9 amino acids) first isolated from rabbit thalamic venous blood in the 1970s. Despite its name, research has examined DSIP across a broad range of neurological contexts beyond sleep regulation, including stress response, nociception, and neuroendocrine signaling.
The FDA’s July 24 review places DSIP in three distinct research categories: opioid withdrawal, chronic insomnia, and narcolepsy. Published preclinical and early clinical literature has examined DSIP’s effects on sleep architecture, opioid receptor interactions, and hypothalamic-pituitary-adrenal (HPA) axis modulation. Its potential role in opioid withdrawal research has attracted particular interest given ongoing research into non-opioid addiction management strategies.
DSIP (Emideltide) is available from Iron Peak Peptides for laboratory research purposes only.
6. Semax
FDA evaluation uses: Cerebral ischemia; migraine; trigeminal neuralgia
Semax is a synthetic heptapeptide (7 amino acids) derived from ACTH(4-7) with a Pro-Gly-Pro C-terminal modification. It has been studied extensively in Russian academic institutions as a nootropic and neuroprotective compound, and is available in some Eastern European countries as a registered pharmaceutical.
The FDA’s July 24 review examines Semax in three neurological research contexts: cerebral ischemia (stroke recovery models), migraine, and trigeminal neuralgia. Published research has examined Semax’s effects on BDNF (brain-derived neurotrophic factor) expression, NGF receptor activity, and neuroprotective signaling following ischemic injury in animal models. Its documented regulatory approval in Russia for stroke treatment represents an established preclinical and clinical research base.
Semax is available from Iron Peak Peptides in lyophilized form (≥98% HPLC purity) for laboratory research use only.
7. Epitalon (Epithalon)
FDA evaluation use: Insomnia
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the St. Petersburg Institute of Bioregulation and Gerontology. It was originally studied as a pineal gland extract with potential effects on telomerase activation, melatonin regulation, and circadian rhythm entrainment.
The FDA’s July 24 review focuses specifically on Epitalon for insomnia research — likely reflecting its studied effects on melatonin secretion and circadian biology. Published preclinical research has examined Epitalon’s effects on pineal gland function, age-related melatonin decline, and sleep architecture in aging animal models. Separate but related lines of research have investigated Epitalon’s potential effects on telomerase activity and cellular senescence, though these are not the FDA’s focus for the July review.
Epitalon is available from Iron Peak Peptides in lyophilized form for laboratory and preclinical research use only.
The 5 Additional Peptides: Future PCAC Meeting
The July 23–24, 2026 meeting covers seven of the peptides removed in 2023. The FDA has confirmed that a second PCAC meeting — scheduled before the end of February 2027 — will consider five additional peptides. The FDA has not yet published the formal agenda for this future meeting.
Based on the 2023 Category 2 removals and subsequent regulatory communications, researchers are tracking which of the original 19 peptides remain unscheduled for review. Iron Peak Peptides will continue to supply these compounds for preclinical research regardless of their compounding pharmacy regulatory status.
What This Means for Preclinical Researchers
The July 2026 PCAC review represents an important regulatory development, but researchers sourcing peptides for laboratory use should understand the distinction between the compounding pharmacy regulatory framework and the research supply framework:
- Research supply: Peptide suppliers like Iron Peak Peptides operate under a research compound framework. Researchers can continue to purchase BPC-157, KPV, TB-500, MOTS-C, Semax, Epitalon, and DSIP for in vitro and in vivo preclinical research regardless of the PCAC outcome. These products are labeled “Not for Human Consumption” and sold for laboratory research only.
- Compounding pharmacy access: The PCAC review specifically concerns whether licensed 503A compounding pharmacies should be permitted to compound and dispense these peptides for patient use with a prescription. This is a distinct regulatory pathway.
- Research documentation: Researchers using these peptides for institutional research should maintain standard documentation protocols: IRB/IACUC approval for animal studies, material safety data (if applicable), and chain-of-custody records for controlled substances (if applicable).
Sourcing the July 2026 PCAC Peptides for Research
Iron Peak Peptides offers all seven peptides under review at the July 2026 FDA PCAC meeting for laboratory and preclinical research use. All products are:
- ≥98% HPLC purity verified
- Mass spectrometry confirmed for sequence and molecular weight accuracy
- Shipped cold (lyophilized powder) from the United States
- Batch-specific quality documentation included with every order
- For research use only — not for human consumption
US researchers can shop by peptide category or search by compound name at ironpeakpeptides.com. IronPeak ships to all 50 US states with 1–2 business day fulfillment.
| Peptide | FDA Review Date | FDA Evaluation Use(s) | Research Category |
|---|---|---|---|
| BPC-157 | July 23, 2026 | Ulcerative colitis | GI / mucosal healing |
| KPV | July 23, 2026 | Wound healing; inflammatory conditions | Anti-inflammatory / skin |
| TB-500 (Thymosin Beta-4) | July 23, 2026 | Wound healing | Tissue repair / angiogenesis |
| MOTS-C | July 23, 2026 | Obesity; osteoporosis | Metabolic / mitochondrial |
| Emideltide (DSIP) | July 24, 2026 | Opioid withdrawal; insomnia; narcolepsy | Neurological / sleep |
| Semax | July 24, 2026 | Cerebral ischemia; migraine; trigeminal neuralgia | Neuroprotective / cognitive |
| Epitalon | July 24, 2026 | Insomnia | Pineal / circadian / longevity |
Frequently Asked Questions
Will the PCAC meeting make these peptides legal for human use?
The PCAC meeting concerns the 503A Bulk Drug Substances List — which governs what licensed compounding pharmacies can produce with a valid prescription from a licensed practitioner. Even if the committee recommends inclusion, these peptides would still require a compounding pharmacy and a licensed prescriber to reach patients. For preclinical research purposes, availability from research suppliers is not affected by the PCAC outcome.
When will the FDA announce its decision after the July meeting?
The FDA typically takes several months to issue a response after PCAC meetings. The July 23–24 meeting is the beginning of a formal review process, not the end. Researchers should monitor the FDA’s PCAC page and the Federal Register for updates.
Can I submit public comments about the July PCAC meeting?
Yes. Public comments on the bulk drug substances being reviewed are accepted through the Federal Register docket. Comments received by July 9, 2026 will be provided to the committee. The docket number is FDA-2026-N-2979, and comments can be submitted via Regulations.gov.
What happens at the future PCAC meeting for the remaining five peptides?
The FDA has scheduled a second PCAC meeting before February 2027 to review five additional peptides from the original 2023 removal list. The formal agenda for that meeting has not yet been published.
Are these peptides available for research in the US right now?
Yes. All seven peptides reviewed at the July 2026 PCAC meeting are available from Iron Peak Peptides for laboratory and preclinical research use. The PCAC review does not restrict research compound availability — it concerns compounding pharmacy access only.
Disclaimer: All products sold by Iron Peak Peptides are intended solely for laboratory and preclinical research use. They are not for human consumption, clinical application, veterinary use, or compounding. Iron Peak Peptides does not provide medical advice, dosing guidance, or treatment recommendations. Regulatory information in this article is provided for informational purposes only and does not constitute legal or compliance advice.
🔬 Explore Research Peptides
- VIP 10mg — $79.00
- TB-500 10mg — $69.99
- GHK-Cu 50mg — $35.00
- DSIP 5mg — $40.00
